Literature DB >> 11081861

Factors associated with false-positive staging of lung cancer by positron emission tomography.

P F Roberts1, D M Follette, D von Haag, J A Park, P E Valk, T R Pounds, D M Hopkins.   

Abstract

BACKGROUND: Positron emission tomography imaging is gaining popularity as a noninvasive staging tool in non-small cell lung cancer. Nonmalignant processes can also affect radio-tracer uptake. This study seeks to identify factors associated with false-positive staging of mediastinal metastases.
METHODS: A retrospective review was performed of 100 patients with early stage non-small cell lung cancer referred for positron emission tomography scan evaluation. All had pathologic confirmation of their disease. Positron emission tomography scans, radiology records, operative reports, and pathology results were reviewed. Patients with positron emission tomography scans interpreted as positive for mediastinal involvement and negative pathology at operation were selected.
RESULTS: Seven patients were found to have a false-positive positron emission tomography evaluation for mediastinal metastases. All but 1 patient had a concurrent inflammatory process or an anatomic factor associated with the false positive. The sensitivity and specificity in detecting involved mediastinal nodes was 87.5% and 90.7%, respectively. The negative predictive value was 95.8%.
CONCLUSIONS: Although positron emission tomography has been established as an accurate modality to stage non-small cell lung cancer, false-positive evaluation of mediastinal metastases can occur in the setting of concurrent inflammatory lung diseases or for centrally located tumors. Pathologic evaluation of mediastinal disease should be pursued whenever suggested by a positive positron emission tomography scan especially in the face of those factors described.

Entities:  

Mesh:

Year:  2000        PMID: 11081861     DOI: 10.1016/s0003-4975(00)01769-0

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  22 in total

1.  The impact of image fusion in resolving discrepant findings between FDG-PET and MRI/CT in patients with gynaecological cancers.

Authors:  Cheng-Chien Tsai; Chien-Sheng Tsai; Koon-Kwan Ng; Chyong-Huey Lai; Swei Hsueh; Pan-Fu Kao; Ting-Chang Chang; Ji-Hong Hong; Tzu-Chen Yen
Journal:  Eur J Nucl Med Mol Imaging       Date:  2003-08-21       Impact factor: 9.236

2.  Preoperative staging of non-small-cell lung cancer: comparison of whole-body diffusion-weighted magnetic resonance imaging and 18F-fluorodeoxyglucose-positron emission tomography/computed tomography.

Authors:  Gregor Sommer; Mark Wiese; Leopold Winter; Claudia Lenz; Markus Klarhöfer; Flavio Forrer; Didier Lardinois; Jens Bremerich
Journal:  Eur Radiol       Date:  2012-07-09       Impact factor: 5.315

3.  Oncologic positron emission tomography: a surgical perspective.

Authors:  Todd O Moore; Landis K Griffeth
Journal:  Proc (Bayl Univ Med Cent)       Date:  2003-01

4.  Early recurrence of completely resected N2-positive non-small-cell lung cancer.

Authors:  Takuma Tsukioka; Noritoshi Nishiyama; Takashi Iwata; Nobuhiro Izumi; Shinjiro Mizuguchi; Ryuhei Morita; Kiyotoshi Inoue; Shigefumi Suehiro
Journal:  Gen Thorac Cardiovasc Surg       Date:  2007-03

5.  Accuracy of positron emission tomography and computed tomography (PET/CT) in detecting nodal metastasis according to histology of non-small cell lung cancer.

Authors:  David E Smith; Julian Fernandez Aramburu; Alejandro Da Lozzo; Juan A Montagne; Enrique Beveraggi; Agustin Dietrich
Journal:  Updates Surg       Date:  2019-09-24

6.  Diffusion-weighted imaging can correctly identify false-positive lymph nodes on positron emission tomography in non-small cell lung cancer.

Authors:  Hiroaki Nomori; Yue Cong; Hiroshi Sugimura; Yoshiaki Kato
Journal:  Surg Today       Date:  2015-12-10       Impact factor: 2.549

Review 7.  Advances in Imaging and Automated Quantification of Malignant Pulmonary Diseases: A State-of-the-Art Review.

Authors:  Bruno Hochhegger; Matheus Zanon; Stephan Altmayer; Gabriel S Pacini; Fernanda Balbinot; Martina Z Francisco; Ruhana Dalla Costa; Guilherme Watte; Marcel Koenigkam Santos; Marcelo C Barros; Diana Penha; Klaus Irion; Edson Marchiori
Journal:  Lung       Date:  2018-10-09       Impact factor: 2.584

8.  Prospective comparison of 18F-FDG PET/MRI and 18F-FDG PET/CT for thoracic staging of non-small cell lung cancer.

Authors:  Julian Kirchner; Lino M Sawicki; Felix Nensa; Benedikt M Schaarschmidt; Henning Reis; Marc Ingenwerth; Simon Bogner; Clemens Aigner; Christian Buchbender; Lale Umutlu; Gerald Antoch; Ken Herrmann; Philipp Heusch
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-08-03       Impact factor: 9.236

9.  18F-FDG PET for the lymph node staging of non-small cell lung cancer in a tuberculosis-endemic country: is dual time point imaging worth the effort?

Authors:  Ruoh-Fang Yen; Ke-Cheng Chen; Jang-Ming Lee; Yeun-Chung Chang; Jane Wang; Mei-Fang Cheng; Yen-Wen Wu; Yung-Chie Lee
Journal:  Eur J Nucl Med Mol Imaging       Date:  2008-02-19       Impact factor: 9.236

10.  False positive diagnosis of malignancy in a case of cryptogenic organising pneumonia presenting as a pulmonary mass with mediastinal nodes detected on fluorodeoxyglucose-positron emission tomography: a case report.

Authors:  Aravind Ponnuswamy; Neeraj Mediratta; Iain D Lyburn; James P Finnerty
Journal:  J Med Case Rep       Date:  2009-11-14
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.